Used in cancer immunotherapy to block the PD-L1 protein on tumor cells, preventing it from suppressing T-cell activity. This enhances the immune system’s ability to detect and destroy cancer cells. Employed in treating various solid tumors, including non-small cell lung cancer, melanoma, and urothelial carcinoma. Often part of checkpoint inhibitor therapy regimens, either as monotherapy or in combination with other immunotherapies or chemotherapies. Supports durable responses in patients with high PD-L1 expression and is being studied in multiple clinical trials for additional cancer types.